linking drug stability to manufacturing physical chemical foundations gabapentin

32
Linking Drug Stability to Manufacturing Physical Chemical Foundations Gabapentin L. E. Kirsch Stability team leader

Upload: zytka

Post on 25-Feb-2016

28 views

Category:

Documents


1 download

DESCRIPTION

Linking Drug Stability to Manufacturing Physical Chemical Foundations Gabapentin. L. E. Kirsch Stability team leader. Stability Team. Linking manufacturing to stability. Manufacturing Stress . API*. (Unstable form). Physical transformation. Chemical transformation. API. Degradant. - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: Linking Drug Stability to Manufacturing Physical Chemical Foundations Gabapentin

Linking Drug Stability to ManufacturingPhysical Chemical Foundations

Gabapentin

L. E. KirschStability team leader

Page 2: Linking Drug Stability to Manufacturing Physical Chemical Foundations Gabapentin

Stability TeamGroup Team member

Minnesota Raj Suryanarayanan (Co-PI)

Aditya Kaushal (post-doc)

Kansas Eric Munson (Co-PI)

Dewey Barich (post-doc)

Elodie Dempah, Eric Gorman (grad. students)

Iowa Lee Kirsch (Co-PI)

Greg Huang (Analytical Chemist)

Salil Desai, Zhixin Zong, Tinmanee Radaduen, Hoa Nguyen, Jiang Qiu (grad students)

Duquesne(Unit-op team Interface)

Ira Buckner

Page 3: Linking Drug Stability to Manufacturing Physical Chemical Foundations Gabapentin

3

Linking manufacturing to stability

API

API*

Degradant

PHYSICAL

TRANSFORMATION Chemica

l

trans

form

ation

(Stable form)

(Unstable form)

Page 4: Linking Drug Stability to Manufacturing Physical Chemical Foundations Gabapentin

4

Gabapentin as a model drug substance

NH2

OH

O

gabapentin(Gaba)

• Multiple crystalline forms• Susceptible to stress-induced physical

transformations• Susceptible to chemical degradation

NH3+

O-

O

NH2

O-

O

NH3+

OH

O

pKa 3.7 pKa 10

KEY QUESTIONS1. Are physical and chemical instability

linked?2. How can manufacturing-induced stress be

incorporated in a quantitative chemical instability model?

Page 5: Linking Drug Stability to Manufacturing Physical Chemical Foundations Gabapentin

Some Crystalline Forms of Gabapentin

5

API form Crystalline

I

II

III

IV

Ibers., Acta Cryst c57, 2001 and Reece and Levendis., Acta Cryst. c64 2008

Transition between forms by mechanical stress, humidity, and thermal stress

Hydrate

Stable polymorph (API)

Intramolecular H-bonding

Page 6: Linking Drug Stability to Manufacturing Physical Chemical Foundations Gabapentin

4 6 8 10 12 14 16 18 20 22

2Theta

Physical transformation by Mechanical Stress

Form II

Form III

Milled Gabapentin

Page 7: Linking Drug Stability to Manufacturing Physical Chemical Foundations Gabapentin

Physical transformation by Humidity

2theta

7

Inte

nsity

47 hrs in 40C 31 %RH29 hrs17 hrs 7 hrs 0 hr

Page 8: Linking Drug Stability to Manufacturing Physical Chemical Foundations Gabapentin

Physical transformation by Thermal Stress

Kaushal and Suryanarayanan., Minnesota Univ. AAPS poster 20098

Page 9: Linking Drug Stability to Manufacturing Physical Chemical Foundations Gabapentin

Aqueous degradation kinetics

OOH

NH2 NH

O

gabapentin lactam

Irreversible cyclization

+ H2O

toxicUSP limit: < 0.4%

Page 10: Linking Drug Stability to Manufacturing Physical Chemical Foundations Gabapentin

Solid state degradation kinetics40 C 5% RH, milled gabapentin

0

1

2

3

4

5

6

7

0 100 200 300 400 500 600

Lact

am (m

ole

%)

hours

initial lactamrapid degradation of process-damaged gaba

autocatalytic lactam formation

Page 11: Linking Drug Stability to Manufacturing Physical Chemical Foundations Gabapentin

11

Solid state Degradation Model

GABA (G)(stable form) LACTAM (L)

autocatalytic branching

spontaneous dehydration

branching termination

LDGk 1

Dk2GABA (D)(unstable form)

DGk3

Hypothesis:Manufacturing stress determines initial conditions (G0, D0 and L0)Environmental (storage) stress determines kinetics (k1, k2 and k3)

Page 12: Linking Drug Stability to Manufacturing Physical Chemical Foundations Gabapentin

Building a quantitative degradation model

12

DrugStability

Compositional Factors

(e.g. excipients)

Environmental Stress

ManufacturingStress

Page 13: Linking Drug Stability to Manufacturing Physical Chemical Foundations Gabapentin

13

Effects of Manufacturing Stress:Initial Lactam and Instability

0 5 10 15 20 25 300.0

0.5

1.0

1.5

2.0

2.5%

lact

am

time(days)

60 min milled

45 min milled

15 min milled

API as received

Thermal stressed at 50 °C, 5%RH

Lactam generated during milling(in-process lactam)

Milling caused faster degradation rate

Page 14: Linking Drug Stability to Manufacturing Physical Chemical Foundations Gabapentin

14

Can Surface Area account for Lactamization Rate Changes upon

Mechanical Stess?

0 5 10 15 200

0.2

0.4

0.6

0.8

1

Specific Surface Area(m2/g)

Lact

amiza

tion

Rate

(mol

e%/d

ay 5

0 °C

)

Samples milled for different time

Sieved aliquots of 15min milled sample

Sieved aliquots of unmilled sample

NO, ALSO increased regions of crystal disorder caused by the mechanical stress.

Page 15: Linking Drug Stability to Manufacturing Physical Chemical Foundations Gabapentin

Mechanical Stress Impact on Lactam Formation at 50 °C: No kinetic effects

15

TreatmentD0(%)

unstressed 0.027

15min milled 0.46

45min milled 0.92

60min milled 1.30

60min

0 200 400 600 800 1000 1200 14000.000

0.500

1.000

1.500

2.000

2.500

3.000

3.500

4.000

4.500

hours

Lact

am m

ole

%

45min

15min

0 min

Page 16: Linking Drug Stability to Manufacturing Physical Chemical Foundations Gabapentin

Effects of Temperature:predicted values based on parameterization of

autocatalytic model

0 50 100 150 200 2500

5

10

15

20

25

time(hours)

Lact

am m

ole%

Gaba 40C 5%RH

Gaba 50C 5%RHGaba 60C 5%RH

Page 17: Linking Drug Stability to Manufacturing Physical Chemical Foundations Gabapentin

17

Effects of Moisture

Page 18: Linking Drug Stability to Manufacturing Physical Chemical Foundations Gabapentin

18

Why moisture appears to slow and shut down lactam formation?

• In general, effect of moisture is NOT to slow reaction rates

• Analytical issue?

• Reversible reaction?

• Formation of stable hydrate?No gabapentin formed from gaba-L in solution or solid state

No hydrate found from XRD patterns

Most gaba-L could be recovered from solid powder, only ignorable gaba-L was detected in saturated salt solution.

Moisture-facilitated termination of branching

Page 19: Linking Drug Stability to Manufacturing Physical Chemical Foundations Gabapentin

19

Effect of Moisture:Shut down Lactam Formation

0

1

2

3

4

0 20 40 60 80 100

Gaba

-L C

once

ntra

tion

(Mol

e %

)

Hours

Pretreated at 5% RH 25°C for 24 hours before thermal stress

Pretreated at 81% RH 25°C for 24 hours before thermal stress

Thermal stress: 50°C 5%RH

Page 20: Linking Drug Stability to Manufacturing Physical Chemical Foundations Gabapentin

0.001

0.01

0.1

1

10

100

1000

104

105

0 10 20 30 40 50 60

Estim

ate

cons

tant

s (r

ate

x 10

6)

Relative Humidity (%)

Humidity effects (40 °C)

20

0.000

1.000

2.000

3.000

4.000

5.000

6.000

7.000

8.000

9.000

10.000

0 100 200 300 400 500 600 700 800

Lact

am m

ole%

hours

5% RH

11% RH

30% RH50% RH

k3 termination

k1 branching

lactam time profiles rate constants vs RH

k2 cyclization

Page 21: Linking Drug Stability to Manufacturing Physical Chemical Foundations Gabapentin

– Mixtures of gabapentin & excipients– Co-milled– Storage conditions: 5 to 50% RH at 50 ˚C

• Excipients (50% w/w)– CaHPO4.2H20 (Emcompress)– Corn starch– Microcrystalline cellulose (Avicel PH101)– HPMC 4000– Colloidal SiO2 (Cab-O-Sil)– Talc (Mg silicate)– HPC (6.5% w/w)

Evaluation of the role of excipients in gabapentin SS degradation

Saturated solution 50˚C

0

10

20

30

40

50

0 100 200 300 400 500

5RH 4:47:40 AM 10/22/2010

gabaAviHPMCCabTalcHPC Calccorngaba obscalc obscorn obsAvi obsHPMC obsCab obsTalc obsHPC obs

Gaba

Starch

CaHPO4SiO2

HPC AvicelHPMC

Talc

Lact

am m

ole

%Time (hr)

Page 22: Linking Drug Stability to Manufacturing Physical Chemical Foundations Gabapentin

Excipient Effectscontrolled temperature (40-60 C) and humidity (5-50% RH)

0 100 200 300 400 500 600 700 8000.000

2.000

4.000

6.000

8.000

10.000

hours

Lact

am m

ole%

0 100 200 300 400 500 600 700 8000.000

4.000

8.000

12.000

16.000

20.000

hours

lact

am m

ole%

No excipient

6.5% HPC

• Crystal damage (D0) during milling• Kinetics of branching(k1) and

termination(k3)

Page 23: Linking Drug Stability to Manufacturing Physical Chemical Foundations Gabapentin

Effect of co-milled excipients on crystal damage during milling

0 5 10 15 20 25

Si02

CaHPO4

Talc

HPMC

HPC (6.5%)

Starch

None

% Unstable Gabapentin (D0)

Excipients50% w/w

Page 24: Linking Drug Stability to Manufacturing Physical Chemical Foundations Gabapentin

Moisture and excipient effectsNo excipient Co-milled excipient (SiO2)

5 %RH 11 %RH30 %RH

50 %RH

11 %RH

30 %RH

50 %RH

5 %RH

24

0

10

20

30

40

50

0 100 200 300 400 500 600

Data 10

BDFH

Lact

am m

ole

%

Time (hr)

0

5

10

15

20

0 100 200 300 400 500 600 700 800

moisture effect gaba50RH

0RH11RH30RH50RH

Page 25: Linking Drug Stability to Manufacturing Physical Chemical Foundations Gabapentin

Effect Moisture on Lactamization Kineticsfor gabapentin/HPC (6.5%) mixtures: blue: HPC and red: no HPC

0.01

0.1

1

10

100

1000

104

105

10 20 30 40 50 60

Estim

ated

con

stan

ts (k

1 106 ,

k 3107 )

Relative Humidity (%)

K (k1/k3)

k1 branching

k3 termination

Page 26: Linking Drug Stability to Manufacturing Physical Chemical Foundations Gabapentin

Linking Stability in Design SpaceManuf.Design SpaceModel

L0D0

Post-Manuf.

Degradation

Model

LtEndof

Expiry

• Key Research Findings• Manufacturing Stress impacts drug stability upon storage:

L0 (in-process lactam) D0 (unstable gabapentin)

• Predictive model for drug stability includes:• Environment factor: temperature () & humidity ()• Compositional factors: both kinetic and initial condition

effects• Manufacturing factors: L0 and D0

• Model validation: completion of long term stability

Page 27: Linking Drug Stability to Manufacturing Physical Chemical Foundations Gabapentin

Measuring the manufacturing stress effects• Physical methods

– Raj Suryanarayanan (University of Minnesota) – Eric Munson (University of Kentucky)

• Chemical and kinetic measurements– Lee Kirsch (University of Iowa

Solid State NMR KansasRaman spectroscopy MinnesotaPowder x-ray diffraction (XRD) MinnesotaDSC/TGA All Water vapor sorption MinnesotaHPLC Iowa

Page 28: Linking Drug Stability to Manufacturing Physical Chemical Foundations Gabapentin

Chromatographic Approach for Manufacturing Stability Measurement

Minutes

1 2 3 4 5 6 7 8 9 10

mAU

0.00

0.25

0.50

0.75

1.00

1.25

1.50

mAU

0.00

0.25

0.50

0.75

1.00

1.25

1.50

4093

741

Gab

apen

tin

3.65

8

2388

5.39

0

4339

La

ctam

7.28

8

3853

9.11

7

Detector 1-210nmhydBt0H

AreaNameRetention Time

Detector 1-210nmhydBt24H

Comparison of HPLC chromatograms before (black) and after (red) thermal stress:

∆ lactam = 0.004%.

Minutes

1 2 3 4 5 6 7 8 9 10

mAU

0

1

2

3

4

mAU

0

1

2

3

4

2801

635

Gab

apen

tin

3.66

8

8278

La

ctam

7.30

7

Detector 1-210nmhydAt0H

AreaNameRetention Time

Detector 1-210nmhydAt24H

Comparison of HPLC chromatograms before (black) and after (red) thermal stress:

∆ lactam = 0.059%.

Minutes

1 2 3 4 5 6 7 8 9 10

mAU

0

5

10

15

20

mAU

0

5

10

15

20

4635

741

Gab

apen

tin

3.61

8

2878

43

7.57

2

(Lactam)

Detector 1-210nmlotAH

AreaNameRetention Time

Detector 1-210nmlotAHbefore

Comparison of HPLC chromatograms before (black) and after (red) thermal stress:

∆ lactam = 0.174%.

Page 29: Linking Drug Stability to Manufacturing Physical Chemical Foundations Gabapentin

Manufacturing-stability measurements

• In process lactam (L0)– Change in lactam levels during specific treatment or unit

operation in % lactam/gabapentin on molar basis• Initial Rate of Lactam Formation (V0 or STS)

– Daily rate of lactam formation upon thermal stress at 50°C under low humidity

• D0 from Chemical Analysis

dayCk

kVD

DkV

o %/37.0)50(2

2

00

020

Page 30: Linking Drug Stability to Manufacturing Physical Chemical Foundations Gabapentin

Insert Sury

Page 31: Linking Drug Stability to Manufacturing Physical Chemical Foundations Gabapentin

Insert Eric

Page 32: Linking Drug Stability to Manufacturing Physical Chemical Foundations Gabapentin

Applied Manufacturing-stability Measurements to Design Space and Risk Assessment

• Laboratory scale stability design space• Pilot scale stability design space• Risk assessment using Manufacturing-

stability Measurements